There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Structure Therapeutics, Inc. Sponsored ADR (GPCR – Research Report), AstraZeneca (AZN – Research Report) and Acadia Healthcare (ACHC – Research Report) with bullish sentiments.
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Leerink Partners analyst David Risinger reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR on November 14 and set a price target of $97.00. The company’s shares closed last Wednesday at $48.32.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Structure Therapeutics, Inc. Sponsored ADR has an analyst consensus of Strong Buy, with a price target consensus of $89.17, implying a 64.9% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $93.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
AstraZeneca (AZN)
In a report issued on November 13, Andrew Berens from Leerink Partners maintained a Buy rating on AstraZeneca, with a price target of $78.00. The company’s shares closed last Wednesday at $63.13, close to its 52-week low of $61.73.
According to TipRanks.com, Berens has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AstraZeneca with a $83.00 average price target, which is a 30.7% upside from current levels. In a report issued on November 9, BMO Capital also maintained a Buy rating on the stock with a $83.00 price target.
Acadia Healthcare (ACHC)
In a report issued on November 14, Whit Mayo from Leerink Partners maintained a Buy rating on Acadia Healthcare, with a price target of $95.00. The company’s shares closed last Wednesday at $74.92.
According to TipRanks.com, Mayo is a 3-star analyst with an average return of
Acadia Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $90.40, representing a 23.0% upside. In a report issued on November 6, TD Cowen also maintained a Buy rating on the stock with a $86.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GPCR:
- Structure Therapeutics reports Q3 EPS (21c), consensus (29c)
- Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
- Structure Therapeutics price target raised to $93 from $58 at Piper Sandler
- Five new option listings and one option delisting on October 25th
- Structure Therapeutics initiated with an Outperform at JMP Securities
